ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. This is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback